Meta-analysis comparing dexmedetomidine versus standard of care for sedation in patients with sepsis
| Autor: | Babikir Kheiri, Sakiru Isa, Bilal Haider Malik, Mohamed M G Mohamed, Pramod Savarapu, Mustafa Hassan, Basel Abdelazeem |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Proc (Bayl Univ Med Cent) |
| ISSN: | 1525-3252 0899-8280 |
| DOI: | 10.1080/08998280.2021.1997063 |
| Popis: | We aimed to evaluate the clinical benefits of dexmedetomidine (DEX) in comparison with the standard of care (SOC) sedation in critically ill, septic patients. Electronic databases (PubMed, EMBASE, Cochrane Central, Scopus, and Google Scholar) were systematically searched to identify only randomized clinical trials performed up until February 12, 2021. The primary outcomes were 28-day mortality, 90-day mortality, and intensive care unit (ICU) length of stay (LOS). We calculated risk ratios (RRs), 95% confidence intervals (CIs) for dichotomous data, and weighted mean differences (WMDs) for continuous data using a random-effects model. Seven randomized clinical trials were included, with a total of 529 patients in the DEX group and 520 patients in the SOC group. Compared with SOC, DEX was associated with a nonstatistically significant reduced 28-day mortality (RR = 0.76; 95% CI [0.51, 1.14]; P = 0.19), 90-day mortality (RR = 0.94; 95% CI [0.75, 1.18]; P = 0.60), and ICU LOS (WMD = −0.85; 95% CI [-2.60, 0.90]; P = 0.34). We conclude that among septic patients on sedation, the use of DEX in the ICU demonstrated no significant difference from SOC sedation protocols with respect to 28-day mortality, 90-day mortality, and total ICU LOS. Our findings suggest that DEX does not confer clinical benefit over SOC sedation in critically ill patients with sepsis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|